JILIN AODONG PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.08 CNY | +2.65% |
|
+2.17% | -0.40% |
| Apr. 17 | Aodong Medicine's 2023 Profit Declines 18%; Revenue Up 20% | MT |
| Apr. 16 | Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 17,020 | 17,098 | 18,034 | - |
| Enterprise Value (EV) 1 | 17,020 | 17,098 | 18,034 | 18,034 |
| P/E ratio | 10.2 x | 12.3 x | 7.52 x | 6.51 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 4.96 x | 4.38 x | 3.73 x |
| EV / Revenue | - | 4.96 x | 4.38 x | 3.73 x |
| EV / EBITDA | - | 10.7 x | 7.17 x | 6.32 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 0.66 x | 0.58 x | 0.54 x |
| Nbr of stocks (in thousands) | 1,135,395 | 1,129,349 | 1,195,895 | - |
| Reference price 2 | 14.99 | 15.14 | 15.08 | 15.08 |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 3,449 | 4,121 | 4,831 |
| EBITDA 1 | - | 1,593 | 2,517 | 2,855 |
| EBIT 1 | - | 1,382 | 2,288 | 2,646 |
| Operating Margin | - | 40.08% | 55.52% | 54.77% |
| Earnings before Tax (EBT) 1 | - | 1,500 | 2,288 | 2,646 |
| Net income 1 | 1,781 | 1,460 | 2,329 | 2,692 |
| Net margin | - | 42.33% | 56.51% | 55.74% |
| EPS 2 | 1.467 | 1.227 | 2.005 | 2.315 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 5.48% | 7.75% | 8.34% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 22.80 | 25.80 | 27.70 |
| Cash Flow per Share 2 | - | 0.0600 | 0.4800 | 0.2400 |
| Capex 1 | - | 385 | 16.8 | 16.6 |
| Capex / Sales | - | 11.16% | 0.41% | 0.34% |
| Announcement Date | 4/18/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.08
CNY
Average target price
22.67
CNY
Spread / Average Target
+50.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.40% | 2.49B | |
| +25.83% | 661B | |
| +28.10% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +15.02% | 231B | |
| +4.83% | 200B | |
| -9.41% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 000623 Stock
- Financials Jilin Aodong Pharmaceutical Group Co., Ltd.
